Takayuki Shimose

Fukuoka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Real-World Safety and Efficacy of Pola-R-CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients.

Real-World Safety and Efficacy of Pola-R-CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients.

Journal: Cancer science

Published: March 05, 2026

A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA).

A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA).

Journal: Journal of cachexia, sarcopenia and muscle

Published: November 20, 2025

Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR).

Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR).

Journal: International journal of hematology

Published: July 24, 2025

Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non-small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102).

Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non-small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102).

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 06, 2025

Platinum plus etoposide with durvalumab for extensive-stage small-cell lung cancer with untreated brain metastases: a multicenter, single-arm phase II trial (LOGiK2001, SPEED).

Platinum plus etoposide with durvalumab for extensive-stage small-cell lung cancer with untreated brain metastases: a multicenter, single-arm phase II trial (LOGiK2001, SPEED).

Journal: ESMO open

Published: March 03, 2025

Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002).

Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 31, 2025

Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

Journal: Oncoimmunology

Published: December 16, 2024

Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003).

Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003).

Journal: JTO clinical and research reports

Published: December 04, 2024

A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non-small cell lung cancer (LOGIK1902).

A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non-small cell lung cancer (LOGIK1902).

Journal: Thoracic cancer

Published: March 23, 2024

Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study).

Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study).

Journal: Therapeutic advances in medical oncology

Published: February 03, 2023

Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003).

Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003).

Journal: Thoracic cancer

Published: October 22, 2022

Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases.

Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases.

Journal: Cancer management and research

Published: October 10, 2022

Showing 1-12 of 33

Last Updated: 09/26/2026